14 -1 (29/1) 2020 — Naimova Sh.A., — THE DEGREE OF SECONDARY OSTEOPOROSIS IN RHEUMATOLOGICAL PATIENTS AND WAYS OF ITS PREVENTION

THE DEGREE OF SECONDARY OSTEOPOROSIS IN RHEUMATOLOGICAL PATIENTS AND WAYS OF ITS PREVENTION

Naimova Sh.A.,-Bukhara State Medical Institute.

Resume,

The study examined the frequency of occurrence and change in bone mineral density – osteopenia and osteoporosis, which is a systemic manifestation of autoimmune inflammation in patients with rheumatoid arthritis and disease of connective tissue. The study involved 80patients aged    40-70   years (mean age 56.3 ± 4,3 years), who were treated at the Department of Rheumatology of the Bukhara regional multidisciplinary medical center, studied risk factors that could cause changes in bone mineral density, as well as the degree of osteoporosis and osteopenia when taking glucocorticosteroids and cytostatics.

Key words: rheumatoid arthritis, inflammation, diffuse diseases of connective tissue, bone mineral density (BMD), osteoporosis, and osteopenia

First page

53

Last page

55

For citation: Naimova Sh.A., The degree of secondary osteoporosis in rheumatological patients and ways of its prevention 1(29)2020 53-55 https://cutt.ly/jvHM6Rq

List of References

  1. Насонов Е.Л., и др. Ревматоидный артрит //Ревматология. Национальное руководство / Е. Л. Насонов, Д. Е. Каратеев, Р. М. Балабанова; под ред. Е.Л. Насонова, В.А. Насоновой. – М., 2008. – С. 290-331.
  2. Верткин А.Л., Моргунов Л.Ю., Наумов А.В. и др. Остеопороз у пациентов с соматической патологией в зависимости от пола. Остеопор и остеопат 2007; 1:25-8.
  3. U.S. Department of Health and Human Services. Bone health and osteoporosis: a report of the surgeon general. Rockville, MD: U.S. Department of Health and Human Services, Office of the Surgeon General, 2004.
  4. Looker A.C., Orwoll E.S., Johnston C.C. Jr. et al. Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res 1997; 12: 1761-8.
  5. Burge R., Dawson-Hughes B., Solomon D.H. et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res 2007; 22:465-75.
  6. Наумов А.В., Коцелапова Э.Ю., Горулева Е.И. и др. “Цель оправдывает средства”, или ещё раз о скрининге и профи­лактике остеопороза. Спр поликлин врача 2009; 7:5-9.
  7. Kanis J.A., Burlet N., Cooper C. et al., on behalf of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 2008; 19:399-428.
  8. Верткин А.Л., Наумов А.В., Шамуилова М.М. и др. Дегенеративно-цистрофические заболевания костно-суставной систе­мы в современной клинике. Решены ли проблемы? Кли^ ге- рош-ол 2008;14(2):53-9.
  9. Van’t Hof R.J., Macphee J., Libouban H. et al. Regulation of bone mass and bone turnover by neuronal nitric oxide synthase. Endocrinology 2004; 145:5068-74.
  10. Hao Y.J., Tang Y., Chen F.B. et al. Different doses of nitric oxide donor prevent osteoporosis in ovariectomized rats. Clin Orthop 2005; 435:226-31.
  11. Caballero-Alias A.M., Loveridge N., Lyon A. et al. NOS isoforms in adult human osteocytes: multiple pathways of NO regulation? Calcif Tissue Int 2004; 75:78-84.

file

download